Inotiv Q3 revenue beats estimates
Overview
Inotiv Q3 fiscal 2025 revenue rises 23.5% to $130.7 mln, beating expectations, per LSEG data
Adjusted EBITDA for Q3 fiscal 2025 beats estimates, reaching $11.6 mln
Company reports Q3 fiscal 2025 net loss of $17.6 mln
Result Drivers
RMS GROWTH - Revenue from Research Models & Services rose 34.1%, driven by increased NHP-related product and service revenue
DSA IMPROVEMENTS - Discovery & Safety Assessment revenue increased 8.9%, attributed to growth in general toxicology, biotherapeutic, and medical device services
INVESTMENT BENEFITS - Integration and optimization investments over the past two years have driven growth in quoting and awards, per CEO Robert Leasure Jr.
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $130.70 mln | $127.10 mln (3 Analysts) |
Q3 Net Income |
| -$17.60 mln |
|
Q3 Adjusted EBITDA | Beat | $11.60 mln | $11 mln (3 Analysts) |
Q3 Operating Income |
| -$5.70 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Inotiv Inc is $5.00, about 58.5% above its August 5 closing price of $2.08
Press Release: ID:nGNX5x5Ykm
